Surgical Oncology
Volume 19, Issue 1 , Pages e47-e55 , March 2010

Pregnancy after breast cancer: A need for global patient care, starting before adjuvant therapy

  • Nathalie Chabbert-Buffet

      Affiliations

    • APHP, Hôpital Tenon, Département de Gynécologie-Obstétrique et Médecine de la Reproduction, 4 rue de la Chine – 75571 Paris Cedex 20, France
    • ER 9, Université Pierre & Marie Curie (Paris 6), Paris, France
    • Réseau Cancer Associe à la Grossesse, Hôpital Tenon, Paris, France
    • Corresponding Author InformationCorresponding author at: Département de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital Tenon, 4 rue de la Chine, 75020 Paris, France. Tel.: +33 1 56 01 77 48; fax: +33 1 56 01 73 17.
    • ,
  • Catherine Uzan

      Affiliations

    • Département de chirurgie, Institut Gustave Roussy, Villejuif, France
    • Réseau Cancer Associe à la Grossesse, Hôpital Tenon, Paris, France
    • ,
  • Joseph Gligorov

      Affiliations

    • Département d'Oncologie médicale, Hôpital Tenon, Paris, France
    • Réseau Cancer Associe à la Grossesse, Hôpital Tenon, Paris, France
    • ,
  • Suzette Delaloge

      Affiliations

    • Département d'Oncologie médicale, Institut Gustave Roussy, Villejuif, France
    • Réseau Cancer Associe à la Grossesse, Hôpital Tenon, Paris, France
    • ,
  • Roman Rouzier

      Affiliations

    • APHP, Hôpital Tenon, Département de Gynécologie-Obstétrique et Médecine de la Reproduction, 4 rue de la Chine – 75571 Paris Cedex 20, France
    • UPRESS 4053, Université Pierre & Marie Curie (Paris 6), Paris, France
    • Réseau Cancer Associe à la Grossesse, Hôpital Tenon, Paris, France
    • ,
  • Serge Uzan

      Affiliations

    • APHP, Hôpital Tenon, Département de Gynécologie-Obstétrique et Médecine de la Reproduction, 4 rue de la Chine – 75571 Paris Cedex 20, France
    • UPRESS 4053, Université Pierre & Marie Curie (Paris 6), Paris, France
    • Réseau Cancer Associe à la Grossesse, Hôpital Tenon, Paris, France

,Accepted 24 March 2009.

References 

  1. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. The New England Journal of Medicine. 1976;294(8):405–410
  2. Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, et al. 1-Phenylalanine mustard (l-PAM) in the management of primary breast cancer. A report of early findings. The New England journal of medicine. 1975;292(3):117–122
  3. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early breast cancer trialists' collaborative group. Lancet. 1992;339(8784):1–15
  4. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. The New England journal of medicine. 2005;353(16):1734–1736
  5. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18(7):1133–1144
  6. National Cancer Comprehensive Network. Available from: <http://www.nccn.org/patients/patient_gls/_english/_breast/contents.asp#>.
  7. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Annals of Oncology. 2005;16(10):1569–1583
  8. Adjuvant online. Available from: <http://www.adjuvantonline.com/breastnew.jsp>.
  9. Nabholtz JM, Gligorov J. The role of taxanes in the treatment of breast cancer. Expert Opinion on Pharmacotherapy. 2005;6(7):1073–1094
  10. Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology. 2006;24(34):5381–5387
  11. Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocrine Reviews. 1996;17(2):121–155
  12. Ruess ML, Kline J, Santos R, Levin B, Timor-Tritsch I. Age and the ovarian follicle pool assessed with transvaginal ultrasonography. American Journal of Obstetrics and Gynecology. 1996;174(2):624–627
  13. Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964–1988 in Ontario, Canada. American Journal of Epidemiology. 1999;150(3):245–254
  14. Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy. Current Opinion in Obstetrics & Gynecology. 2005;17(1):21–26
  15. Kil WJ, Ahn SD, Shin SS, Lee SW, Choi EK, Kim JH, et al. Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients. Breast Cancer Research and Treatment. 2006;96(3):245–250
  16. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. Journal of Clinical Oncology. 1999;17(8):2365–2370
  17. Swain S, Land S, Ritter M, Costantino J, Cecchini R, Mamounas E, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Research and Treatment. 2009;113(2):315–320
  18. Christodoulakos G, Lambrinoudaki I, Panoulis C, Sioulas V, Rizos D, Caramalis G, et al. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene. Maturitas. 2005;50(4):321–330
  19. Harper-Wynne CL, Sacks NP, Shenton K, MacNeill FA, Sauven P, Laidlaw IJ, et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. Journal of Clinical Oncology. 2002;20(4):1026–1035
  20. Lasco A, Cannavo S, Gaudio A, Morabito N, Basile G, Nicita-Mauro V, et al. Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women. European journal of endocrinology/European Federation of Endocrine Societies. 2002;147(4):461–465
  21. Ellmen J, Hakulinen P, Partanen A, Hayes DF. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. Breast Cancer Research and Treatment. 2003;82(2):103–111
  22. Whitehead E, Shalet SM, Jones PH, Beardwell CG, Deakin DP. Gonadal function after combination chemotherapy for Hodgkin's disease in childhood. Archives of disease in childhood. 1982;57(4):287–291
  23. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer. 1983;52(6):988–993
  24. Wallace WH, Shalet SM, Crowne EC, Morris-Jones PH, Gattamaneni HR, Price DA. Gonadal dysfunction due to cis-platinum. Medical and Pediatric Oncology. 1989;17(5):409–413
  25. Larsen EC, Muller J, Rechnitzer C, Schmiegelow K, Andersen AN. Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH <10IU/l. Human Reproduction (Oxford, England). 2003;18(2):417–422
  26. McCarthy NJ. Care of the breast cancer survivor: increased survival rates present a new set of challenges. Postgraduate medicine. 2004;116(4):39–402, 5-6
  27. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9(6):466–472
  28. Stearns V, Schneider B, Henry NL, Hayes DF, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nature Reviews. 2006;6(11):886–893
  29. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monographs. 1986;(1):105–109
  30. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. Journal of Clinical Oncology. 2006;24(36):5664–5671
  31. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104(8):1575–1579
  32. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. American Journal of Clinical Oncology. 2007;30(2):126–132
  33. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Human Reproduction (Oxford, England). 2006;21(10):2583–2592
  34. Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Human Reproduction Update. 2005;11(1):69–89
  35. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology. 2007;12(2):141–147
  36. Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Human Reproduction (Oxford, England). 2003;18(2):323–327
  37. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Human Reproduction (Oxford, England). 2002;17(12):3065–3071
  38. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertility and Sterility. 2005;83(4):979–987
  39. Mohamed KA, Davies WA, Lashen H. Antimullerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertility and Sterility. 2006;86(5):1515–1517
  40. Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Investigation. 2008;26(3):286–295
  41. de Bruin JP, Bovenhuis H, van Noord PA, Pearson PL, van Arendonk JA, te Velde ER, et al. The role of genetic factors in age at natural menopause. Human Reproduction (Oxford, England). 2001;16(9):2014–2018
  42. Nippita TA, Baber RJ. Premature ovarian failure: a review. Climacteric. 2007;10(1):11–22
  43. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin's disease. Medical and Pediatric Oncology. 1996;27(2):74–78
  44. Schilsky RL, Sherins RJ, Hubbard SM, Wesley MN, Young RC, DeVita VT. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. American Journal of Medicine. 1981;71(4):552–556
  45. Magelssen H, Melve KK, Skjaerven R, Fossa SD. Parenthood probability and pregnancy outcome in patients with a cancer diagnosis during adolescence and young adulthood. Human Reproduction (Oxford, England). 2008;23(1):178–186
  46. Gerber B, Dieterich M, Muller H, Reimer T. Controversies in preservation of ovary function and fertility in patients with breast cancer. Breast Cancer Research and Treatment. 2007;
  47. Pritchard KI. Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift?. Journal of Clinical Oncology. 2002;20(24):4611–4614
  48. Swain SM, Jeong J-H, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, et al. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. San Antonio Breast Cancer Symposium 2008 Abstract #75.
  49. Early Breast Cancer Trialists' Collabortaive Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet 2005; 365 (9472): 1687–717.
  50. Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: international breast cancer study group trial 13–93. Journal of Clinical Oncology. 2006;24(9):1332–1341
  51. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology. 2006;24(36):5769–5779
  52. Vanhuyse M, Fournier C, Bonneterre J. Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Annals of Oncology. 2005;16(8):1283–1288
  53. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncology. 2006;7(10):821–828
  54. Parton M, Smith IE. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. Journal of Clinical Oncology. 2008;26(5):745–752
  55. Rabaglio M, Aebi S, Castiglione-Gertsch M. Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncology. 2007;8(10):940–949
  56. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide- induced ovarian follicular depletion in rhesus monkeys. Biology of Reproduction. 1995;52(2):365–372
  57. McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocrine Reviews. 2000;21(2):200–214
  58. Pru JK, Tilly JL. Programmed cell death in the ovary: insights and future prospects using genetic technologies. Molecular Endocrinology. 2001;15(6):845–853
  59. Brougham MF, Wallace WH. Subfertility in children and young people treated for solid and haematological malignancies. British Journal of Haematology. 2005;131(2):143–155
  60. Recchia Francesco, Saggio Gaetano, Amiconi Giovanna, Blasio Anna Di, Cesta Alisia, Candeloro Giampiero, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 2006;106(3):514–523
  61. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Molecular and Cellular Endocrinology. 2002;187(1–2):93–105
  62. Franke HR, Smit WM, Vermes I. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy. Gynaecological Endocrinology. 2005;20(5):274–278
  63. Pereyra Pacheco B, Mendez Ribas JM, Milone G, Fernandez I, Kvicala R, Mila T, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecologic Oncology. 2001;81(3):391–397
  64. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 2006;106(3):514–523
  65. Poirot C, Vacher-Lavenu MC, Helardot P, Guibert J, Brugieres L, Jouannet P. Human ovarian tissue cryopreservation: indications and feasibility. Human Reproduction (Oxford, England). 2002;17(6):1447–1452
  66. von Wolff M, Donnez J, Hovatta O, Keros V, Maltaris T, Montag M, Salle B, Sonmezer M, Andersen CY. Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy – a technique in its infancy but already successful in fertility preservation. European Journal of Cancer, 2009 March [Epub ahead of print]
  67. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Human Reproduction (Oxford, England). 2003;18(1):90–95
  68. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. Journal of Clinical Endocrinology & Metabolism. 2006;91(10):3885–3890
  69. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–4353
  70. Requena A, Herrero J, Landeras J, Navarro E, Neyro JL, Salvador C, et al. Use of letrozole in assisted reproduction: a systematic review and meta-analysis. Human Reproduction Update. 2008;14(6):571–582
  71. Gook DA, Edgar DH. Human oocyte cryopreservation. Human Reproduction Update. 2007;13(6):591–605
  72. Chian R-C, Huang JYJ, Tan SL, Lucena E, Saa A, Rojas A, et al. Obstetric and perinatal outcome in 200 infants conceived from vitrified oocytes. Reproductive BioMedicine Online. 2008;16:608–610
  73. Cooper DR, Butterfield J. Pregnancy subsequent to mastectomy for cancer of the breast. Annals of Surgery. 1970;171(3):429–433
  74. Ariel IM, Kempner R. The prognosis of patients who become pregnant after mastectomy for breast cancer. International Surgery. 1989;74(3):185–187
  75. Gelber S, Coates AS, Goldhirsch A, Castiglione-Gertsch M, Marini G, Lindtner J, et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol. 2001;19(6):1671–1675
  76. Kroman N, Jensen MB, Melbye M, Wohlfahrt J, Mouridsen HT. Should women be advised against pregnancy after breast-cancer treatment?. Lancet. 1997;350(9074):319–322
  77. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: “healthy mother effect”. American Journal of Obstetrics and Gynecology. 1994;170(3):818–823
  78. von Schoultz E, Johansson H, Wilking N, Rutqvist LE. Influence of prior and subsequent pregnancy on breast cancer prognosis. Journal of Clinical Oncology. 1995;13(2):430–434
  79. Ives A, Saunders C, Bulsara M, Semmens J. Pregnancy after breast cancer: population based study. BMJ (Clinical Research Ed). 2007;334(7586):194
  80. Blakely LJ, Buzdar AU, Lozada JA, Shullaih SA, Hoy E, Smith TL, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004;100(3):465–469
  81. Averette HE, Mirhashemi R, Moffat FL. Pregnancy after breast carcinoma: the ultimate medical challenge. Cancer. 1999;85(11):2301–2304
  82. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. Journal of Clinical Oncology. 2001;19(4):980–991
  83. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. Journal of Clinical Oncology. 2008;26(5):778–785
  84. Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS collaborators' group. Journal of Clinical Oncology. 2006;24(21):3361–3366
  85. Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. International Journal of Cancer. 2005;117(6):988–991
  86. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 1999;354(9190):1586–1590
  87. Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, et al. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes & Control. 2008;19(10):1111–1119
  88. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. Journal of Clinical Oncology. 2008;26(16):2630–2635
  89. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opinion on Pharmacotherapy. 2007;8(8):1039–1058
  90. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Seminars in Oncology. 2006;33(Suppl. 8):2–7
  91. Jensen BV. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Seminars in Oncology. 2006;33(Suppl. 8):15–21
  92. van Dalen EC, van der Pal HJH, van den Bos C, Kok WEM, Caron HN, Kremer LCM. Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines. European Journal of Cancer. 2006;42(15):2549–2553
  93. Goethals I, De Winter O, De Bondt P, De Sutter J, Dierckx R, Van De Wiele C. The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage. Annals of Oncology. 2002;13(9):1331–1339
  94. Tralins AH. Lactation after conservative breast surgery combined with radiation therapy. American Journal of Clinical Oncology. 1995;18(1):40–43
  95. Langagergaard V, Gislum M, Skriver MV, Norgard B, Lash TL, Rothman KJ, et al. Birth outcome in women with breast cancer. British Journal of Cancer. 2006;94(1):142–146
  96. Dalberg K, Eriksson J, Holmberg L. Birth outcome in women with previously treated breast cancer – a population-based cohort study from Sweden. PLoS Medicine. 2006;3(9):e336
  97. Rouzier R, Uzan C, Lesieur B, Vercambre M, Chabbert-Buffet N. Are pregnancy and ART reasonable after breast cancer? MT Medecine de la Reproduction. Gynécologie Endocrinologie. 2008;10(4):238–242

PII: S0960-7404(09)00046-2

doi: 10.1016/j.suronc.2009.03.009

Surgical Oncology
Volume 19, Issue 1 , Pages e47-e55 , March 2010

Article Tools

* Image Usage & Resolution